Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 8853 results

  1. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Glatiramer acetate depot for multiple sclerosis [TSID10620]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MT512)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  4. Digital technologies delivering CBT for insomnia in adults

    In development Reference number: GID-HTE10068 Expected publication date:  06 January 2027

    Health technology evaluations
    In development

  5. Zavegepant for treating acute migraine [TSID11998]

    Awaiting development Reference number: GID-TA11527 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]

    Awaiting development Reference number: GID-TA11069 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 20 April 2026.

    Technology appraisal guidance
    In consultation

  8. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development Reference number: GID-NG10216 Expected publication date:  29 July 2026

    NICE guideline
    In development

  10. Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]

    Awaiting development Reference number: GID-TA11835 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

    In development Reference number: GID-TA10752 Expected publication date:  10 July 2026

    Technology appraisal guidance
    In development

  13. Suspected sepsis in pregnancy: recognition, diagnosis and early management

    In development Reference number: GID-NG10468 Expected publication date:  17 February 2027

    NICE guideline
    In development

  14. Gender Incongruence Services for Children and Young People

    In development Reference number: GID-QS10193 Expected publication date:  02 December 2026

    Quality standard
    In development

  15. Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]

    In development Reference number: GID-TA11649 Expected publication date:  14 October 2026

    Technology appraisal guidance
    In development